Pfizer should partner with Sanofi


It's day three of the Pfizer-Sanofi merger watch. Sanofi-Aventis shares are up 5.5 percent on continued rumors of a Pfizer investment in its business. Now, experts are saying that a Sanofi acquisition wouldn't be prudent for Pfizer--but a partnership would.

If Pfizer just bought a stake in Sanofi, it could share in the French company's revenues. Sanofi would get access to Pfizer's U.S. sales force. And the companies wouldn't have to get the French government's blessing on this sort of deal--a blessing that might be hard to come by.

- read the report from Fortune

Virtual Clinical Trials Summit

Virtual Clinical Trials Summit: The Premier Educational Event Focused on Decentralized Clinical Trials

In this virtual environment, we will look at current and future trends for ongoing virtual trials, diving into the many ways companies can improve patient engagement and trial behavior to enhance retention with a focus on emerging technology and harmonized data access across the clinical trial system.

Related Articles:
Pfizer-Sanofi match not made in heaven? Report
Pfizer, Wyeth merger bad idea? Report

Read more on: Pfizer | Sanofi-Aventis